

REMODULIN® (treprostinil sodium) Injection Patient Assistance Program

Patient Assistance Program (PAP)

The REMODULIN Patient Assistance Program provides access to medication and supplies for patients who cannot afford therapy, are not adequately insured, or are close to the lifetime limit of their current insurance policy and includes:

- Indigent coverage
- Underinsured/“gap” coverage
- Lifetime cap assistance

Coverage When Patients Need It

Only REMODULIN PAP covers the cost of REMODULIN therapy for **patients who get within \$300,000** of exhausting their lifetime insurance policy limits.

- This assistance helps patients’ insurance plans reserve money for potential transplants or other disease management needs

Additionally, United Therapeutics will provide REMODULIN **regardless of previous PAH therapy.**


- This includes patients previously on epoprostenol who have transitioned to REMODULIN

Coordinated Benefits

REMODULIN PAP is fully coordinated by our contracted Specialty Pharmacy Services (SPS) providers.

- SPS providers are responsible for collecting the necessary patient demographic, financial, and clinical information and overseeing the completion of the application form
- SPS providers maintain a detailed and retrievable record of all communications, correspondence, and activities related to the PAP including the dispensing of product, supplies, and equipment without charge to the PAP patient
- SPS providers use reasonable attempts to help locate alternative third-party payer benefits for each PAP patient, where applicable

Patient costs of REMODULIN treatment may vary depending on individual dose, third-party payer allowances, and selected SPS providers.



PATIENT ASSISTANCE PROGRAM

For more information, please contact United Therapeutics at:

1-888-485-8350 | www.REMODULIN.com



Indications

REMODULIN® (treprostinil sodium) Injection is indicated as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II–IV symptoms to diminish symptoms associated with exercise. REMODULIN is indicated to diminish the rate of clinical deterioration in patients requiring transition from Flolan® (epoprostenol sodium) for Injection; the risks and benefits of each drug should be carefully considered prior to transition.

Important Safety Information

REMODULIN Injection is contraindicated in patients with hypersensitivity to REMODULIN, its ingredients, or similar drugs. REMODULIN is a potent pulmonary and systemic vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. REMODULIN inhibits platelet aggregation and, therefore, may increase the risk of bleeding, particularly in patients on anticoagulants. REMODULIN should be used only by doctors experienced in the treatment of PAH, and must be started in a setting with equipment and personnel for emergency care. Abrupt withdrawal or sudden large reductions in dosage of REMODULIN may result in worsening of PAH symptoms and should be avoided. Caution should be used in patients with hepatic or renal problems. The most common side effects of REMODULIN included those related to the method of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment with narcotics or discontinuation of REMODULIN. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising, and pain were most common (results from an uncontrolled, open-label study). General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilation, and edema. Generalized rashes, sometimes macular or papular in nature, and cellulitis have been infrequently reported in postmarketing experience.

F.P.O.
P.I.


REMODULIN[®]
(treprostinil sodium) Injection